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INTRODUCTION 
Oropharyngeal cancer is the fifteenth most common cancer world-wide and the 
prevalence is particularly high in men.1 An estimated incidence of 3, 00,373 cases and 
145,353 deaths from oral cancer have occurred in 2012 worldwide.1 The highest rates 
are found in Melanesia, South-Central Asia, and Central and Eastern Europe.2 In India, 
oral cancer is the third leading site among males and females among all tobacco related 
cancers and is the second most common cancer among males. It is the third leading 
cancer for male and seventh leading cancer for females in Chennai.3 Oral cancer 
accounts for over 30% of all cancers in the country with age-adjusted rates being 20 per 
100,000 population.4 
Oral cancer may develop from oral potentially malignant disorders (OPMD) or 
de novo from normal mucosa.5 Potentially malignant disorders of the oral cavity 
comprises of  leukoplakia, erythroplakia, palatal lesions in reverse smokers, sub 
mucous fibrosis, actinic keratosis, lichen planus, discoid lupus erythematosus, 
immunodeficiency in relation to cancer predisposition and some inherited cancer 
syndromes.6,7,8 The clinical significance of oral potentially malignant disorders lies in 
its association with malignant transformation into Oral Squamous Cell Carcinoma. Oral 
leukoplakia and erythroplakia has been identified as the one with the highest malignant 
transformation rates.9 
The prevalence of leukoplakia varies from 0.2% to 4.9% while the global 
prevalence is estimated to be 2.6%.10 They have been reported to show a significant 
tendency to malignant transformation from 0.13 to 6%, and rising to 14% or higher 
when dysplasia is present.11 In India, the prevalence of leukoplakia varies from 0.2% to 
5.2% and malignant transformation ranges between 0.13% and 10% according to 
various studies.12   
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The annual incidence of oral leukoplakia among subjects greater than 15 years 
of age was reported as 0.2% to 11.7% in different populations of India.13 
 Tobacco and alcohol are strong risk factors for both oral cavity cancers (OCC) 
and oropharyngeal cancers.14,15 Tobacco use is responsible for one-third of all cancer-
related deaths.16 Several studies have shown the role of tobacco products and alcoholic 
beverages in the induction of oral precancerous lesions.17 Cross-sectional studies in 
Chennai regarding prevalence of oral lesions in relation to habits have shown a 
prevalence rate of 4.1%.18 Presently, India has more than 274.9 million tobacco 
consumers. According to the Global Adult Tobacco Survey (GATS) 2010 report, 60% 
of tobacco users in India currently use only smokeless tobacco and an additional 15% 
are mixed users, (both smokeless tobacco and smoked tobacco).19 
Detection of asymptomatic cancers could be a problem in dental screening due 
to poor attendance of high-risk patients but oral precancerous lesions provide a long 
preclinical phase during which high-risk patients could be identified to provide 
interventions.20 Early detection and management of oral pre-malignant lesions is vital 
to prevent malignant transformation and thus improve the survival rate and quality of 
life (QoL).  
Review of literature has proven the effectiveness of tobacco cessation 
counselling on the cessation of habit and reversal of lesions.21-27 However, cessation of 
tobacco use has deep rooted behavioural pattern that is highly resistant to change and 
relapse rates are high.28 
Treatment of oral potentially malignant disorders include non-surgical and 
surgical management. Systematic review of non-surgical treatment have shown that 
none of the non-surgical intervention is beneficial when compared with the placebo. 
Adverse effects have been reported on the long term use of these chemo preventive 
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agents. As leukoplakias are not morbid or lethal by themselves, have a relatively low 
risk of transformation and have a long clinical course the proposed treatments should 
have minimal adverse effects in terms of incidence and severity.29   Surgical resection 
following long term follow up is also recommended in the literature for the management 
of leukoplakia but surgical management too has its own demerits and is invasive in 
nature.30 
Exploration of scientific literature reveals that there is no regular treatment 
protocol for the treatment of oral premalignant lesions. Thus, the need to rely on 
indigenous health care is warranted for management of oral potentially malignant 
disorders.  
The World Health Organization estimates that 80% of the world's inhabitants 
rely mainly on traditional medicines for their health care.31 A traditional formulation of 
herbal medicine usually contains a variety of constituents such as polyphenols, 
alkaloids, flavonoids, triterpenoids, and other secondary metabolites that have 
anticancer/ antimutagenic properties.32,33  
Triphala is the most commonly used Indian herbal formulation, consisting equal 
parts of three medicinal dried plant fruits; Emblica officinalis Gaertn., [Indian 
gooseberry or Aamla], Terminilia bellerica Roxb. [Belleric myrobalan or Baheda] and 
Terminilia chebula Retz. [Chebulic Myrobalan or Harad]. The differential effect of 
Triphala on normal and tumour cells seems to be related to its ability to evoke 
differential response in intracellular reactive oxygen species generation.34 A study by 
Deshpande et al., 2014 has proved Triphala to have great potential for reversal of oral 
precancerous lesions.35 
Quercus infectoria (Oak gall) is one of the traditional plants that have great 
potential on medicinal purpose and have been reported to possess antioxidant and 
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antibacterial properties.36,37 The galls of Quercus infectoria comprise a large amount of 
tannins, gallic acid, syringic acid, ellagic acid, β-sitosterol, amentoflavone hexamethyl 
ether, isocryptomerin, methyl betulate, and methyl oleanate and hexagalloyl glucose. 
The plant is reported to possess antidiarrhoeal, anti-amoebic, antibacterial, antifungal, 
larvicidal, antidiabetic, local anaesthetic, antiviral, anti-inflammatory, hepatoprotective 
and wound healing properties.38   
Sarwat Sultana et al.,2012 has proved Quercus infectoria to be a potent 
chemopreventive agent as it suppresses Fe-NTA-induced renal carcinogenesis and 
oxidative and inflammatory response in Wistar rat.39  Kaur et al.,2008 reported Quercus 
infectoria is capable of protecting against oxidative damage to lipids and proteins and 
also chelates metal ions that catalyze the generation of oxidants.40 A study by Wan-
Ibrahim et al.,2010   on the anti-oxidant properties of  20 edible plants has shown that 
Oak gall had the highest radical scavenging activity(86.8%) compared to others.41 
However there are very limited in vivo studies till date  to evaluate the effectiveness of 
oak gall on the reversal of oral precancerous lesions.  
The use of traditional medicinal plants parts and plant derived compounds has 
untied a new dimension in the field of cancer research. Yet there are not adequate 
scientific evidences to prove their effectiveness in cancer prevention and management. 
Intervention of premalignant lesions/conditions at an earlier stage by cost effective 
methods such as tobacco cessation counselling and use of traditional medicines will not 
only reduce the economic burden of treating the disease but also will substantially 
increase the life span and thus the quality of life of the individual. To the best of our 
knowledge, there are limited studies evaluating the effectiveness of traditional 
medicines as an adjuvant to tobacco cessation counselling in the reversal of oral 
potentially malignant disorders. Thus, the aim of the study is to compare the 
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effectiveness of Oak gall oil and Triphala oil as an adjuvant to tobacco cessation 
counselling in the reversal of oral leukoplakia at a Public Dental hospital in Chennai 
city.  
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REVIEW OF LITERATURE 
                    The purpose of identifying potentially malignant disorders of the oral 
cavity is to initiate timely and adequate intervention and, where possible to prevent 
malignant transformation or enable early diagnosis of malignancy.42 In order to conduct 
treatment for oral leukoplakia the degree of epithelial dysplasia must be assessed. In 
the presence of moderate or severe epithelial dysplasia, surgical treatment is 
recommended. An extensive review of surgical management of oral potentially 
malignant disorders has shown that the evidence for its success is lacking, and in some 
cases, there have been reports of increased recurrence of malignancy following surgical 
excision.43 The associated morbidity of surgery also makes it less appealing for 
extensive lesions.42 Nonsurgical treatment management of oral leukoplakia offers 
minimal adverse effects to patients, especially for patients with widespread lesions that 
involves a large area of the oral mucosa or patients with medical problems and 
consequently high surgical risks. Additionally, potential advantages of the nonsurgical 
treatment of oral leukoplakia include easy application that does not require treatment at 
a medical centre and relative low cost.44 Various non-surgical treatments have been 
reported on the management of oral leukoplakia but currently there is no consensus 
achieved among them.29 An extensive review of literature on the various non-surgical 
treatment modalities involved in the management of oral leukoplakia are given below: 
Chemo preventive agents in the treatment of leukoplakia 
Kaugars et al [1996] has reviewed the use of antioxidant supplements in the 
treatment of human oral leukoplakia such as Beta carotenoids, retinol, retinoids, 
ascorbic acid, and alpha-tocopherol. The percentage of patients with clinical 
improvement ranged from 14.8% to 71%.45  
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Lodi et al [2002] in his systematic review of randomized trials for the treatment 
of oral leukoplakia have enrolled studies involving Vitamin A, retinoids, bleomycin, 
mixed tea and beta carotene. It was concluded that although some treatments may be 
effective in healing oral leukoplakia, they do not seem to be able to prevent relapses 
and malignant change. Topical 13-cis-retinoic acid, 200,000 IU per week of vitamin A, 
and mixed tea did not cause any adverse effects. Topical bleomycin, systemic 13-cis-
retinoic acid (1 to 2 mg/kg/day), vitamin A (300,000 IU per week), and beta carotene 
(360 mg/week) caused adverse effects of various severity in 100 percent, 79 percent, 
26 percent, and 9 percent of patients, respectively.46 
Lodi et al [2008] in his review on the intervention for treating oral leukoplakia 
has concluded that none of the treatments studied was shown to be effective in 
preventing malignant transformation of leukoplakias.29 
Ribeiro et al [2010] on his extensive review on the non-surgical treatment 
modalities of oral leukoplakia has concluded that studies showed a rate higher than 50% 
of clinical resolution with photodynamic therapy, beta-carotene, lycopene, or        
vitamin A. Few studies have reported rates of recurrence from 5 to 67% and of 
malignant transformation from 8 to 23%. The review has highlighted that randomized 
controlled trials for nonsurgical treatment of oral leukoplakia demonstrate no evidence 
of effective treatment in preventing malignant transformation and recurrence. It 
reinforces that even after clinical resolution, oral leukoplakia should be regularly 
followed.44 
Nagao et al [2015] conducted a randomized clinical trial with low-dose of beta-
carotene and vitamin C supplements for the treatment of oral leukoplakia. 46 
leukoplakia patients were recruited who were ex-smokers or non-smokers. Data from 
this study does not support the recommendation of beta-carotene combined with 
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vitamin C for the chemoprevention of oral cancer when tested on otherwise healthy 
subjects living in well-nourished countries.47 
Tobacco cessation counselling in the treatment of oral leukoplakia  
A decrease in the prevalence of oral leukoplakia after tobacco cessation has been 
observed in many studies, confirming an etiological role. 
  Banoczy [1971] in a  clinicopathologic study of 165 oral leukoplakia cases 
followed up over a period of 20 years proved that following the elimination of 
etiological factors, mainly smoking 43.2 percent of oral leukoplakias resolved.21 
  In Roed-Petersen’s study [1982], smoking cessation for at least one year caused 
resolution of leukoplakia in 58.3 percent of the cases.22 
Silverman et al [1984] in his study on two hundred fifty-seven patients with 
oral leukoplakia followed for an average period of 7.2 years. All lesions were more than 
one cm in size and had been present and observed for a minimum of 6 months. Of the 
initial biopsies, 235 revealed a benign hyperkeratosis and 22 others contained some 
degree of epithelial dysplasia. Seventy-three percent of the patients used tobacco, with 
cigarette usage being the predominant form. There appeared to be a beneficial effect of 
decreased risk for malignant transformation when tobacco users discontinued their 
habits (44%).23 
Gupta et al [1986], conducted a house-to-house survey and selected 36,471 
tobacco chewers and smokers from the rural population in three areas of India. By 
personal advice and via the mass media they were encouraged to give up their tobacco 
habits. The follow up rate was 97%.  It was found that after a cessation intervention 
among 36,471 Indian tobacco users, the five-year age-adjusted incidence rate of 
leukoplakia was four to six times lower among both men and women than the non-
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intervention group thus proving the etiological and beneficial role of tobacco and its 
cessation. 24 
In a study of 3,051 male U.S. military trainees by Martin et al [1999], 302 
individuals were using smokeless tobacco, 39.3 percent had leukoplakia compared to 
1.5 percent among non-users. After six weeks of tobacco cessation, 97.5 percent of 
leukoplakia lesions showed complete resolution clinically.25 
Shiu et al [2000] studied the effects of betel nut chewing, smoking and alcohol 
on the occurrence of leukoplakia and its malignant transformation to oral carcinoma 
and has found that cessation of smoking may reduce by 36% leukoplakia cases, while 
elimination of betel nuts may prevent 62% of leukoplakia and 26% of malignant 
transformation to oral carcinoma.26 
A case study by Othman Shibly [2008] on the resolution of oral lesions after 
tobacco cessation with a follow up period of two weeks has shown a complete 
resolution of oral white lesions and improvement in overall oral health of the patients.27 
Studies on anti-oxidant properties of plant phenolic compounds 
Newmark, H.L., [1996] in his study has proved that plant products with 
phenolic compounds have significant antioxidant properties.33 
Wahle et al [2010] has extensively reviewed the role of plant phenolics in the 
prevention and treatment of cancer.it has been described in the review that plant 
phenolics appear to have both preventive and treatment potential in combating cancer.48 
Arulmozhi et al [2013] in her study has proved that ellagic acid (nonflavonoid 
phenolics) encapsulated chitosan nanoparticles exhibit significant cytotoxicity in KB 
cells in a dose-dependent manner with a very low IC50 value compared to the free 
ellagic acid.49 
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Danaraddi et al. [2014] has reviewed the role of dietary supplements which are 
rich in phytochemicals such as spirulina, selenium, green tea, neem, Tomatoes 
(lycopene), turmeric (curcumin), and some medicinal mushrooms in chemoprevention 
of oral cancer.50 
Triphala as a potent anti-oxidant 
Kaur et al [2002] has done a study to evaluate an antimutagenic potential of 
water, chloroform and acetone extracts of Triphala and has proved the anti-mutagenic 
activity of Triphala.51 Triphala and its individual components are capable of scavenging 
free radicals DPPH, superoxide, and nitric oxide (Naik et al., 2005; Jagetia et al., 
2004). 52 
Sandhya et al [2006] has investigated the cytotoxic effects of Triphala on 
human breast cancer cell line (MCF-7) and transplantable mouse thymic lymphoma 
(barcl-95) and has concluded that the differential response of normal and tumour cells 
to Triphala in vitro and the substantial regression of transplanted tumour in mice fed 
with Triphala points to its potential use as an anticancer drug for clinical treatment.53 
Yan Shi et al  [2008] has done a study to elucidate the molecular mechanism of 
Triphala against human pancreatic cancer in the cellular and in vivo model and has 
proved that Triphala is effective in inhibiting the growth of human pancreatic cancer 
cells in both cellular and in vivo model.34 
Wongnoppavich [2009] in his review on the role of Triphala in cancer treatment 
has concluded that Triphala has high potentials for inhibition and prevention of 
mutagenesis and metastasis of cancer cells.54 
Deshpande et al [2014] found that 34 teenagers among the 1095 children 
screened had aceto white lesions. Triphala mouth rinse was given as intervention along 
with tobacco cessation to 34 patients and was followed for a period of nine months. 
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Histological findings after 9 month use of Triphala mouth rinse revealed no changes in 
cells in 23 (85.2%), hyperkeratinisation in 2 (7.4%). Hyperkeratinization and 
spongiosis was evident in 1 (3.7%), mild pleomorphism in 1 (3.7%). The authors have 
concluded that Triphala proved to be effective in reversal of the lesions and confirmed 
the promising role of Triphala as a potential chemo- preventive drug.35 
Oak gall as a potent antioxidant  
Kaur et al [2008] has demonstrated that Quercus infectoria (QI) galls possess 
potent antioxidant activity, when tested both in chemical as well as biological models.38 
Umachigi et al  [2008] revealed that ethanolic extracts of the galls of QI 
contains high amount of tannins, presence of gallic acid, ellagic acid, syringic acid, iso-
sitosterol and amenotoflavone, implied that tannin is one of the active compounds 
which may be responsible for the antiproliferative activity.55 
Hasmah et al [2010] in a study to evaluate Q.infectoria as an antiproliferative 
agent towards cervical cancer cells (HeLa) and ovarian cancer cells (Caov-3) has 
suggested that QI galls extracts have potential to be used as an anticancer agent. In this 
study it was proved that all the crude extracts of QI galls had IC50 less than 100 μg/ml 
towards both HeLa and Caov-3 cells.56 
Rehman et al [2012] in his study to evaluate the chemo preventive effect of 
Quercus infectoria against chemically induced renal toxicity and carcinogenesis has 
concluded that Quercus infectoria is a potent chemo preventive agent and suppresses 
Fe-NTA-induced renal carcinogenesis and oxidative and inflammatory response in 
Wistar rat.39 
In a study on antibacterial and antioxidant activity of Oak gall  extracts by  Ayub 
Ebadi Fathabad et al  [2016]  it was proved that water extract of Quercus infectoria 
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galls had high antioxidant activities as measured by DPPH scavenging (30/15±0.83 μg 
/ml) and β-carotene linolic acid (89/4±1.11/ml).57 
Studies on the management of leukoplakia have proved that there is no strong 
evidence supporting an effective treatment in preventing malignant transformation of 
leukoplakia. Treatments may be effective in the resolution of lesion but with relapses 
and adverse effects. Various in-vitro studies have investigated the efficacy of Oak gall 
and Triphala, concluding that both Triphala and Oak gall possess significant anti-
oxidant properties. Yet there are no studies done to the best of our knowledge to 
evaluate the effectiveness of Oak gall oil and to compare it with that of Triphala oil for 
the reversal of oral leukoplakia. 
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AIM AND OBJECTIVES 
AIM: 
          The aim of the study is to compare the effectiveness of Oak gall oil with Triphala 
oil as an adjuvant to tobacco cessation counselling in the reversal of oral leukoplakia at 
a Public Dental hospital in Chennai city. 
 OBJECTIVES: 
1. To assess the effectiveness of Oak gall oil as an adjuvant to tobacco cessation 
counselling in the reversal of oral leukoplakia both clinically and histopathologically. 
2. To assess the effectiveness of Triphala oil as an adjuvant to tobacco cessation 
counselling in the reversal of oral leukoplakia both clinically and histopathologically. 
3. To compare the effectiveness of Oak gall oil with Triphala oil as an adjuvant to 
tobacco cessation counselling for the reversal of oral leukoplakia both clinically and 
histopathologically. 
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MATERIALS AND METHODS 
The double blind, parallel, randomized clinical trial conducted on tobacco users 
diagnosed with oral leukoplakia had an allocation ratio of 1:1. Institutional Ethics 
Committee of the Tamil Nadu Government Dental College and Hospital, Chennai, 
Tamil Nadu approved the study (Approval No.R.C.No:0420/DE/2016). The trial was 
registered in the clinical trial registry of India (CTRI/2016/10/007415) and is reported 
in accordance with the CONSORT guidelines with extension for herbal interventions.  
As per the protocol for Ethical approval, the inclusion criteria for the sample 
comprised of current tobacco users with oral leukoplakia and having mild or moderate 
dysplasia histologically. The pilot study concluded that the prevalence of dysplasia 
among oral leukoplakia was minimal. Hence the inclusion criteria for the study has been 
modified as current tobacco users with pre-diagnosed oral leukoplakia irrespective of 
presence or absence of dysplasia.  
Participants 
The trial was conducted under an institutional (hospital) setting among the adult 
patients pre-diagnosed with oral leukoplakia (by an expert from the Department of Oral 
medicine and Radiology of Tamil Nadu Government Dental College and Hospital). The 
recruitment period for the trial was from April 2016 to September 2016. The eligibility 
criteria for the recruitment of the study were: 
Inclusion criteria: 
1. Adults aged 18 year and above 
2. Current tobacco users* pre-diagnosed with oral leukoplakia** (irrespective of 
presence or absence of dysplasia) 
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Operational definitions: 
*Current tobacco users - Current tobacco user is defined as an individual who is using 
1 or more tobacco products for the past 30 days from the time of recruitment.   
**- Leukoplakia: A white plaque of questionable risk having excluded (other) known 
disease or disorders that carry no increased risk for cancer.58 
Exclusion criteria 
1. Subjects with malignant tumours of oral cavity 
2. Subjects with any systemic diseases.  
3. Subjects who were physically and mentally challenged. 
4. Subjects with known hypersensitivity to toluidine blue. 
5. Subjects with dental conditions such as orthodontic appliances or prostheses that may 
interfere with the examination. 
6. Subjects who were currently receiving any type of cessation, alcohol or illicit drug 
treatment at the time of recruitment. 
7. Subjects who were under medication for psychiatric illness, cardiovascular diseases, 
8. Leukoplakia with p2 and px grading of histopathological evaluation (Vanderwaal     
et al 2000)9 
Sample size  
Pilot study was conducted to calculate the sample size. Based on earlier studies 
for the treatment of oral leukoplakia, the anticipated overall response rate in the 
comparison group was estimated at 50%.The sample size required for the trial was 
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estimated to be 12 patients per group. Assuming a possible drop-out rate of 15%, the 
required sample size was set at 15 subjects per group. 
Patient recruitment and randomization 
The study was conducted at the Department of Public Health Dentistry, Tamil 
Nadu Government Dental College and Hospital, Chennai. Participants who met the 
inclusion criteria formed the study population. The purpose of the study was clearly 
explained to the participants. Information sheet was given in Tamil (Annexure I) or 
English version (Annexure II) and written informed consent was obtained from those 
who were willing to participate in either Tamil (Annexure III) or English version 
(Annexure IV). 
 The case record form (Annexure VI) used for data collection comprised of the 
demographic data, complete personal and medical history, assessment of tobacco usage 
(type, number, duration and the frequency of the habit), nicotine addiction (Fagerstrom 
scale (Todd Heatherton, et al. 1991) for nicotine dependence - smokeless/smoke form), 
a comprehensive clinical examination of the oral cavity, clinical and histological 
evaluation of the lesion and the follow up details.  
Baseline assessment: 
Clinical evaluation of the lesion 
 The lesion was evaluated in context of shape, size in square milli-meter, 
consistency, surface texture, induration and ulceration. Measurement was carried out 
using metal rulers graduated in millimeters. (Annexure V) The area of a lesion was 
obtained by multiplying the longest length by the greatest perpendicular breadth. In 
case of multiple lesions, the largest lesion was considered as the index lesion. The lesion 
was also colour photographed for the purpose of comparative assessment.                       
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Van der Waal et al., 2000 classification of leukoplakia was adopted for clinical and 
histopathological staging of leukoplakia (Table 1):  
S.No Precancerous 
lesion 
Grading and staging 
(Van der Waal et al 2000)9 
1 Leukoplakia L (size of the leukoplakia)  
L1- Size of single or multiple leukoplakias together <2 cm  
L2- Size of single or multiple leukoplakias together 2-4 cm  
L3- Size of single or multiple leukoplakias together >4 cm  
Lx- Size not specified  
P (pathology)  
P0 - No epithelial dysplasia (includes "perhaps mild epithelial 
dysplasia") 
P1- Mild or moderate epithelial dysplasia 
P2 -Severe epithelial dysplasia (includes "perhaps carcinoma 
in situ")  
Px -Absence or presence of epithelial dysplasia not specified 
in the pathology report  
OL-staging system  
Stage 1  L1P0 
Stage 2  L2P0 
Stage 3  L3P0 or L1L2P1 
Stage 4  L3P1 or LP2  
 
As per the clinical requirements of the participants, elimination of local 
irritating factors such as removal of plaque and calculus, selective grinding of sharp 
tooth, correction of ill-fitting dentures, correction of faulty restorations, and extraction 
of grossly decayed were carried out to achieve homogeneity among the study 
participants. 
Laboratory procedure: 
All participants were subjected to laboratory procedures which  included tests 
for haemoglobin, bleeding time, clotting time, total leukocyte count, differential count, 
erythrocyte sedimentation rate (ESR), peripheral smear and ELISA test for HIV. 
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After determining the eligibility, baseline clinical evaluation and laboratory 
investigation, all the participants were subjected to an initial toluidine blue staining and 
an incisional biopsy of the lesion using a 6 mm punch.  
Toluidine blue staining59 (Mashberg, 1980) 
  Every participant underwent a toluidine blue staining at baseline and at the end 
of three months to screen for dysplastic changes and to mark the site for biopsy. 
Instruction was given to rinse the mouth twice with water for 20 seconds to remove 
debris. Pre rinse with 1% acetic acid for 20 seconds was done to remove ropey saliva 
followed by 1% toluidine blue application with cotton swab or as a rinse and left for 20 
seconds. Post rinse with 1% acetic acid was done twice to reduce the mechanically 
retained stain. Finally rinsed with water. The stain uptake of the lesion was assessed 
and categorised. Dark royal blue was considered as positive, light blue as doubtful while 
no colour as negative. (Annexure V) 
Oral Punch biopsy 
A histopathological analysis by incisional punch biopsy was performed at 
baseline and at the end of three months by an expert at the Department of Oral and 
Maxillofacial Surgery. A 6mm disposable punch was used for obtaining the biopsy 
specimen for all the participants. The histopathological analysis of the biopsy specimen 
was carried out at the Department of Oral and Maxillofacial Pathology (Annexure V). 
Randomization was done after histopathological evaluation into Oak gall (OG) group 
and Triphala (TP) group.   
Randomisation 
The trial drugs were dispensed by a research assistant and the allocation was 
done by computer-generated list of random numbers. Participants were allocated to 
either of the treatment groups by simple randomization in the ratio of 1:1. Allocated 
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concealment was done by sequentially numbered opaque sealed envelopes [SNOSE]. 
The envelopes were maintained in the possession of chief investigator. The envelopes 
were opened only prior to intervention after patient enrolment and after receiving the 
patient’s consent.  
The principal investigator recruited the participants and was blinded to the 
participants’ group allotments. The Oak gall oil and Triphala oil were dispensed in a 
non-transparent bottles which were identical in appearance. They were prepacked in 
bottles and consecutively numbered for each participant according to the randomisation 
schedule. Each participant was assigned a code number and received the interventions 
in the corresponding prepacked bottle. The trial drugs were matched in context for taste, 
colour and quantity. Thus both the investigator and the participants were blinded about 
the treatment groups. The subjects were allocated to receive the trial intervention (Oak 
gall or Triphala oil) for a period of three months.  
Intervention 
         The intervention for the study participants comprised of Tobacco cessation 
counselling followed by systemic administration of multivitamin tablets for both the 
groups and topical administration of Oak gall oil to OG group and Triphala oil to TP 
group. 
Tobacco cessation counselling (TCC): 
Participants were counselled based on the 5’A strategy (Ask, Advice. Assess, 
Assist, Arrange).60 Posters, pamphlets and video clippings were used as aids for basic 
health education. Cognitive behavioural therapy comprised of cognitive– behavioural 
cessation and relapse prevention strategies and the sessions included discussion of 
barriers to cessation, previous quit attempts, risky situations, and benefits observed 
after quitting.61 
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The principal investigator attended a three day intensive training programme 
on counselling for tobacco cessation at the Adyar cancer institute, Chennai before the 
commencement of the trial. Tobacco cessation counselling with motivation and 
reinforcement was given at baseline, 15th day (II TCC), 30th day (III TCC), 6th week 
(IV TCC).  
Oak gall and Triphala oil (Fig 1) 
The herbal medicine intervention used in this trial was Oak gall (Quercus 
infectoria) and Triphala oil (equal parts of Emblica officinalis Gaertn., [Indian 
gooseberry or Aamla], Terminilia bellerica Roxb. [Belleric myrobalan or Baheda] and 
Terminilia chebula Retz. [Chebulic Myrobalan or Harad]). 
Oak gall and Triphala are registered for use as a natural health care product in 
India and are thoroughly reviewed in the Indian medicinal literature.62,63 Oak gall and 
Triphala has been used in the Indian medicinal literature for the treatment of mouth 
ulcers.64,65,66 It has been recommended for use as both external and internal preparations 
in Indian medicinal literature. 65,66   
Toxicity studies on Oak gall and Triphala has proved that these medicines are 
relatively safe up to the dose of 2g/kg and 240 mg/kg respectively. 67, 52 
Dried fruits of Oak gall and Triphala were obtained from local market and their 
authenticity was verified at Captain Srinivasa Murthy Regional Ayurveda Drug 
Development Institute, Chennai [Authentication No: F.No.1-24/sample 
testing/CSMRADDI/2016-17/360 (Annexure VII)]. In vitro analysis of anti-oxidant  
properties of  Oak gall and  Triphala oil  was carried out as a part of the study which 
showed that the anti-oxidant properties of Oak gall  and Triphala oil was analogous to 
that of the Ascorbic acid and Gallic acid which were used as the standards in the assays. 
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The herbal formulations for both the groups were designed by a Siddha 
physician and the oil preparation of Oak gall and Triphala was done by a qualified 
pharmacist by using standardized operating procedures (SOP).The dried fruits of equal 
parts of Emblica officinalis Gaertn., [Indian gooseberry or Aamla], Terminilia bellerica 
Roxb. [Belleric myrobalan or Baheda] and Terminilia chebula Retz. [Chebulic 
Myrobalan or Harad and the dried galls of Oak gall was powdered and mixed with 
coconut oil in the ratio of 1: 5 (1 part of powder of oak gall or Triphala to five parts of 
pure coconut oil). Both the oils were dispensed in a non-transparent 100 ml plastic 
bottles. 
Oak gall oil was administered to OG Group and Triphala oil to TP Group. Both 
the groups were instructed to apply 2 ml of the herbal oil for a period of three months 
over the lesion three times a day using a cotton applicator and were also instructed not 
to eat or drink for 30 minutes after the application.  
Primary and secondary outcomes 
The primary endpoint or outcome with respect to effectiveness of oak gall oil 
or Triphala oil was the comparison of the clinical and histological reversal of oral 
leukoplakia. The objective clinical response was evaluated by bi-dimensional 
measurement of the lesions and colour photography. The objective clinical response 
was categorized as follows68: 
Complete response— disappearance or no evidence of any measurable lesion.  
Partial response— decrease in the cross-sectional areas of a measurable leukoplakia 
lesion by at least 50% in the product of the two longest diameters of a single lesion in 
the absence of new ‘‘in field’’ lesions;  
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Stable disease—decrease in the cross-sectional area of a measurable leukoplakia lesion 
by less than 50% of the product (or sum of products) of measured lesion diameter in 
the absence of new ‘‘in field’’ lesions;  
Progressive disease—increase in the product (or sum of products) of the measured 
lesion diameter by greater than 25% or development of a new ‘‘in field’’ leukoplakia 
lesion. 
           Clinical response was also graded into a binary response into responders and 
non-responders (Responders were those who showed a complete or partial clinical 
response; non-responders were those showed a stable or progression clinical response).  
Histologic evaluation of all biopsies were performed independently by oral 
pathologists who were blinded to treatment groups. Biopsy samples were scored 
accordingly into a 5-point ordinal scale as Normal epithelium, squamous cell 
hyperplasia, mild dysplasia, moderate dysplasia, severe dysplasia, and carcinoma in situ 
and were ranked as 0, 1, 2, 3, and 4 respectively. Histopathological response was also 
graded into a binary response into responders and non-responders (Responders were 
those who showed histopathological response; non-responders were those who do not 
show histopathological response in histopathological grading). 
Self-reported abstinence from tobacco habit and compliance of the drug was 
assessed as secondary outcome at every visit till the end of three months. Self-reported 
abstinence was grouped into no change in the tobacco habit, reduced use in the tobacco 
habit, stopped use, lost to follow up and relapse. The quit status of the participants were 
also graded into a binary response as quitters and non-quitters.  
Compliance: The compliance to medication was reviewed every 15th day till the third 
month. Patients were instructed to return the empty bottles at each visit to assess the 
compliance.  The subject was deemed to be compliant in this study if the average oil 
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used at every visit was ≥ 80% (i.e., ˂ 20ml of the oil remained at end of each visit).  
The average compliance of each treatment group was calculated separately. 
After the trial commencement no changes to trial outcomes were made. Patients 
were followed up every 15th day till the end of six weeks and at the end of third month. 
Clinical measurement of the lesion and colour photography was done at the baseline, 
6th week and third month. Oral incisional punch biopsy was performed at baseline and 
at the end of third month to grade the lesion histopathologically and to assess the 
reversal of lesion. Self -reported abstinence from the tobacco habit was assessed at the 
end of six weeks and at the end of third month.  The participants were reminded of the 
follow up sessions through telephone and written instructions in their respective 
outpatient card.  
Interim analyses and stopping guidelines 
No interim analysis was made after the commencement of the trial.  
Stopping rules: 
Stopping rules were set for the trial as follows: 
1. Progression of the disease during the trial period despite receiving the intervention  
2. Reversal of the lesion prior to trial period  
3. Severe adverse effects during the intervention period 
Statistical analysis 
                        The collected data was assessed for normality by Kolmogorov- Smirnov 
and Shapiro-Wilks tests. The Normality tests revealed that some variables followed 
Normal distribution. Therefore to analyse the data both parametric and non-parametric 
tests were applied. Chi-square tests of association for statistical significance was used 
to  evaluate the effects of age, religion, marital status, socio-economic status, tobacco 
habit type of tobacco product, level of dependence, alcohol use, site of lesion, size of 
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lesion, number of sites, type of lesion, clinical response, histopathological response, 
quit status and compliance between the treatment groups. 
Outcome analyses was conducted among those participants who completed the 
trial. Participants who showed complete or partial response were deemed as clinical 
responders and those with stable or progressive disease as non-responders to the 
treatment. 
To compare the mean values between groups, independent samples t-test was 
applied. To compare proportions between groups, Chi-Square test was applied and if 
any expected cell frequency was less than five then Fisher’s exact test was used. 
Repeated measures of ANOVA (GLM) was used to compare mean values between time 
points and groups. Significance level was fixed as 5% (α = 0.05) .The collected data 
was entered into Microsoft excel sheet and master table (Table 2, 2.1) was prepared and 
subjected to statistical analysis using SPSS version 22. 
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TABLE 2: MASTER TABLE FOR DATA ANALYSIS 
S.no Group Name Age Sex Religion 
Marital 
status 
SES 
Tobacco 
habit 
Type of 
tobacco 
Yrs. of 
tobacco 
use 
Fagerstrom 
Smoking 
Fagerstrom 
Smokeless 
Alcohol 
use 
Site 
of 
lesion 
Size 
No. 
of 
sites 
Type  
Clinical 
responders 
HPE 
responders 
Quit 
status  
Compliance 
1 1 Perummal 53 1 1 1 2 1 2 35 0 - 1 2 2 1 2 2 2 2 2 
2 1 Chandrasekar 38 1 1 1 2 2 4 5 - 0 1 1 3 2 1 2 1 1 1 
3 1 MohammadAli 52 1 2 1 1 3 1,2,3 25 0 0 0 2 2 1 2 1 3 2 2 
4 1 Anbazhagan 40 1 1 1 1 1 1 35 2 - 1 2 2 2 1 2 2 2 2 
5 1 Hussain 40 1 2 1 2 1 1 25 1 - 1 0 3 2 2 3 4 3 3 
6 1 Devaraj 43 1 1 1 1 3 1,3 39,4 0 1 1 1 1 1 1 1 2 1 1 
7 1 Magarajan 52 1 1 1 1 1 2 23 3 - 1 2,3 4 1 2 3 4 3 3 
8 1 Tamilarasan 25 1 1 1 1 3 1,2,3 12 0 0 1 1 3 2 1 3 4 3 3 
9 1 Kabali 53 1 1 1 2 3 1,2,3 2,2 3 1 1 2 2 2 2 2 2 2 2 
10 1 vetrivel 40 1 1 1 3 1 1 20 0 - 0 2 2 1 2 2 2 2 1 
11 1 Subramani 63 1 1 1 1 1 1,2 33 3 - 1 2,7 4 1 1 1 1 2 1 
12 1 Ragu 26 1 1 0 3 3 1,3 22,6  0 0 1 4 1 2 1 3 4 3 3 
13 1 Sridhar 26 1 1 0 4 3 1,3 3 0 0 1 4 3 1 1 1 3 1 2 
14 1 Rajasekar 39 1 1 1 3 2 4 3 - 2 0 1 3 2 2 1 3 1 1 
15 1 Karthick 31 1 1 1 1 2 3 6 - 2 1 0 2 2 2 1 1 1 1 
1 2 Kumar 54 1 1 1 1 1 2 39 2 - 1 2 1 1 1 1 3 2 1 
2 2 Rajendran 41 1 1 1 1 1 2 21 1 - 1 2 3 1 2 3 4 3 3 
3 2 Suriya 21 1 1 0 2 2 3 3 - 1 1 1 2 2 1 3 4 3 3 
4 2 Ezhumalai 49 1 1 1 1 1 1 20 3 - 0 1 2 2 1 1 2 2 2 
5 2 vincent 40 1 3 1 1 2 3 20 - 2 1 1 2 2 1 1 2 1 1 
6 2 Mani 29 1 1 1 1 2 3 15 - 2 1 1,4 2 1 1 3 4 3 3 
7 2 Babu 46 1 1 1 1 2 3 15 - 3 1 2 2 2 2 1 2 2 1 
8 2 Dinesh 22 1 1 0 3 2 3 3 1 0 1 1 3 2 1 1 3 1 2 
9 2 Deepak 26 1 1 1 1 3 1,3 8 1 1 1 0,5 3 1 1 3 4 3 3 
10 2 Kotti 40 1 1 1 2 1 1 15 2 - 1 1 3 2 2 2 3 2 2 
11 2 Peter 45 1 3 1 1 1 2  2 - 1 2 2 1 2 2 2 1 1 
12 2 Vasantha sekar 48 1 3 1 1 3 1,2,3 25 0 1 1 2,4 1 1 1 1 1 1 1 
13 2 Robby 40 1 3 1 1 2 3 10 - 0 0 1 2 2 1 1 1 1 1 
14 2 Maqbhul 41 1 2 1 1 1 1 21 1 - 0 1 2 2 1 1 2 1 1 
15 2 Lawrence 21 1 3 0 1 3 1,2,3 5,3 1 0 1 2 3 1 1 3 4 3 3 
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TABLE 2.1: CODING SHEET FOR MASTER TABLE 
 
Group 1-Oak gall 
2-Triphala 
Sex 1-male 
2-female 
Religion 1-Hindu 
2-Muslim 
3-Christian 
4-Others 
Marital status 0-Unmarried 
1-Married 
Socioeconomic status 0-lower class 
1-upper lower 
2-lower middle 
3-upper middle 
4-upper class 
Tobacco habit 
 
1-smoking 
2-smokeless 
3-both 
Type of tobacco 
 
1-cigar 
2-beedi 
3-mawa 
4-pan masala 
5-gutka 
6-Hans 
7-Snuf 
8-betel quid 
Site of lesion 0-Right buccal mucosa 
1-Left  buccal mucosa 
2-Bilateral buccal mucosa 
3-palate 
4-tongue 
5-gingiva 
6-multiple 
7-lips 
Fagerstrom score 
Smoking form 
0-very low 
1-medium 
2-high 
3-very high 
Fagerstrom score 
smokeless form 
0-very low 
1-medium 
2-high 
3-very high 
Alcohol use 0-No alcohol 
use 
1-Alcohol use 
Type of leukoplakia 
 
1-homogenous 
2-non homogenous 
Size of the lesion 1-< 2 
2- 2-4 cm 
3-> 4-3 
4-unspecified 
Clinical responders/Non 
responders 
1-Responders 
2-Non responders 
3-Loss to follow up 
Number of sites 1-multiple sites 
2-single site 
Quit status 1-quit 
2-not quit 
3-Loss to follow up 
Histopathological 
responders/Non 
responders 
1-Responders 
2-Non 
responders 
3-Not consented 
4-Loss to follow 
up 
Compliance 1-compliant 
2-non compliant 
3- Loss to follow up 
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Photographs of dried fruits of Triphala (Emblica officinalis Gaertn., Terminalia 
chebula Retz. and Terminalia bellerica Roxb.) 
 
Photograph 1. Emblica officinalis Gaertn. 
 
 Photograph 2. Terminalia chebula Retz.  
 
 Photograph.3. Terminalia bellerica Roxb. 
 
1.1 1.2 
2.1 2.2 
3.1 3.2 
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 Photograph.4 Dried galls of Quercus infectoria Oliv. (OAK GALL) 
 
 Photograph.5 Powdered form of Triphala and Oak gall 
   
 Photograph.6 Oil preparation of Triphala and Oak gall in a non-transparent 
plastic bottle 
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5.1 5.2 
6.1 6.2 
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RESULTS 
A total of 1354 individuals with tobacco habit were screened for oral 
leukoplakia during the recruitment period. Thirty eight individuals with oral 
leukoplakia were assessed for eligibility criteria. Five subjects were excluded as they 
did not fulfill the inclusion criteria. Three Subjects did not consented for the trial and 
were excluded. 30 subjects consented for the trial. Therefore a total number of 30 
participants were included at the baseline for evaluation. These thirty participants were 
randomized into two groups with an allocation ratio of 1:1 with 15 subjects in OG 
group and 15 subjects in TP group.  
The demographic characteristics, tobacco habits and clinical findings were 
comparable in the two groups. There were 8 subjects in OG and 7 subjects in the TP 
group who had completed both clinical and histopathological evaluation at the end of 
three months.  
Among the study population 6 subjects (3 in OG group and 3 in TP group) were 
assessed clinically without histopathological evaluation at the end of three months. The 
reasons for not undergoing post biopsy at the end of three months were fear, personal 
reasons and subjective clinical improvement expressed among individuals. 4 Subjects 
in the OG group and 5 subjects in the TP arm had loss to follow up visits. Therefore, 
21 subjects (11 subjects in the OG group and 10 subjects in the TP group) were 
available at the end of 3 months for primary outcome analyses. The dropout rate in OG 
and TP group in this trial was found to be 26.7% and 33.3% respectively.    
The recruitment of participants in this study is depicted by the CONSORT flow 
chart given below (Fig.1): 
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Figure 1: CONSORT Flow Diagram showing inclusion and exclusion criteria, and 
patient disposition. 
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             Participant’s demographic characteristics, risk factors, clinical and histological 
features of the oral leukoplakia are shown in Table 3. 
Demographic characteristics 
A total number of 30 male participants reported in this study and there were no 
female participants. The mean age of the study participants was 39 years (SD ± 11.18). 
Among the study participants, 73.3% (n=22) were Hindus, 16.7% (n=5) were 
Christians and 10% (n=3) were Muslims. There were 88.3% (n=25) married and 16.7% 
(n=5) unmarried among the study population. Kuppuswamy socioeconomic status 
scale (July 2016) indicated that 63.3% (n=19) of study participants belonged to upper 
–lower class, 20% (n=6) belong to lower –middle class 13.3% (n=4) to upper –middle 
class and 3.3% (n=1) belonged to upper class and none of the participants belong to 
lower class. (Table 3) 
Tobacco habit 
The study revealed that 40% (n=12) of participants used smoking form of 
tobacco, 30% (n=9) of participants used smokeless form of tobacco and 30% (n=9) 
used both smoking and smokeless form. Among the smoking form cigar (20%) was 
found to be more prevalent and mawa (23.3%) was found to be the common form of 
smokeless tobacco. There is no statistical difference regarding the type of tobacco use 
between the study groups (p=0.252). (Table 3) 
Very low dependence was the predominant level of dependence as assessed by 
Fagerstrom scale of dependence for smoking form and smokeless form of tobacco in 
the OG group and was found to be 58.3% and 55.6% respectively. 
 Medium level of dependence was the predominant level of dependence as 
assessed by Fagerstrom scale of dependence for smoking form and smokeless form of 
tobacco in the TP group was found to be 50% and 33.3% respectively. There was a 
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statistical difference (p=0.028) between the level of dependence for smoking form 
between the OG group and TP group. Alcohol dependence was found among 80% 
(n=24) of the participants and 20% (n= 6) had no habit of consuming alcohol. 
Clinical evaluation of the lesion 
There were 30 cases of leukoplakia reported during the study period. Left 
buccal mucosa (36.7%) was found to be the most common site followed by bilateral 
buccal mucosa (33.3%), right buccal mucosa (6.7%) among the treatment groups. 
(Table 3) 
Among the trial groups, 13.3% of the lesions were less than 2cm in diameter, 
46.7% were of 2-4cm in diameter, 33.3% were greater than 4 cm in diameter and 6.7% 
were of unspecified size. There is no statistical difference (p= 0.683) in the size of the 
lesion in both the OG and TP group. 53.3% (n=16) of the participants had lesion at a 
single site and 46.7% (n=14) patients had multiple sites of lesion. (Table 3) 
Non-homogenous type of leukoplakia was found among 53.3% and 
homogenous in 46.7% of the participants in OG group. Whereas in the TP group the 
non-homogenous constituted 26.7% and homogenous being 73.3%. (Table 1)  At the 
baseline the mean size of the lesion in the OG group was 441.07mm2 and the mean size 
in the TP group was 361.93mm2.   
Histopathological response revealed that there were 10 participants in the OG 
group with non-dysplastic lesions and 5 participants with dysplastic lesions. Similarly 
there were 10 participants with non-dysplastic lesions and 5 participants with dysplastic 
lesions in the TP group. (Table 3) 
 Per protocol analyses was carried out for those participants who completed the 
trial. Analysis of missing data by intention to treat analysis (ITT) was not carried out 
as the drop out in this trial was greater than 20%. ITT may modify the outcome of the 
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trial by creating heterogeneity between the treatment groups due to the combination of 
non-compliant, dropouts and compliant subjects during the evaluation of outcome. 
Moreover ITT is more prone to type II error.  
 Therefore primary outcome analyses was performed for those 21 participants 
who completed the trial and underwent both clinical and histopathological evaluation 
and only clinical evaluation. 
Clinical response within groups:  
Clinical response was evaluated for 21 participants (OG group n=11, TP group 
n =10) with a response rate of   45.5 % in the OG group and 70 % in the TP group. 
 (Fig 2) 
Clinical response to OG group: 
Clinical response was evaluated in 11 participants in the OG group (n=15) who 
had clinical assessment done at the end of three months. Clinical grading of leukoplakia 
revealed that none (n=0) showed complete clinical response, 45.5% (n=5) showed 
partial clinical response, 54.5% (n=6) showed stable clinical response and none (n=0) 
showed progression of disease. (Table 4) 
Clinical response to TP group 
Clinical response evaluated for the 10 participants of TP group who completed 
the trial revealed that 20% (n=2) showed complete clinical response, 50 % (n=5) 
showed partial clinical response and 30 % (n=3) showed stable clinical response and 
none showed progression of disease. (Table 4) 
Within groups comparison by repeated measures of ANOVA (Fig 3) at 
baseline, sixth week and third month with a Greenhouse-Geisser correction, determined 
that the size of the lesion (mean square millimeter) differed between time points with 
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statistical significance (p=0.003), which infers that there is a decrease in the size of the 
lesion at various time points in both the groups. (Table 7, 7.1) 
Histopathological response within groups 
Histopathological response to OG group: 
            Histopathological findings of pre-treatment biopsy for eight participants who 
had completed the trial in the OG group (n=15) revealed orthokeratosis in 62.5% (n=5) 
of the participants, hyperplasia was found in 50% (n=4) of the participants, mild 
dysplasia was found in 25% (n=2) participants. The post treatment biopsy done at the 
end of three months for these participants showed reversal of mild dysplasia to 
hyperplasia in two participants, stable response  in six participants.   
Histopathological response to TP group: 
Histopathological evaluation for 7 subjects were available at the end of three 
months for primary outcome analysis in the TP group. There were 71.4% (n=5) 
participants with orthokeratosis, 42.9% (n=3) participants with hyperplasia and 28.6% 
(n=2) with mild dysplasia in baseline histopathological evaluation. The post treatment 
biopsy at the end of three months revealed reversal of mild dysplasia to hyperplasia in 
two participants. The histopathological response was stable in 4 participants and there 
was progression of disease seen in one participant from hyperplasia to mild dysplasia.  
Comparison of clinical response between Oak gall and Triphala group 
Clinical grading of leukoplakia into stable, partial, complete and progressive 
response was done. Chi-square test done to compare the clinical response between the 
groups showed that there is no statistical difference in the clinical response between 
the groups (p=0.228). (Table 4) Comparison of clinical response of OG and TP group 
by independent sample t- test revealed that the difference between the clinical outcome 
seen between the groups is statistically insignificant (p=0.444). (Table 6). Between 
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groups comparison by repeated measures of ANOVA at baseline, sixth week and third 
month with a Greenhouse-Geisser correction determined that the decrease in the size 
of the lesion (mean square millimeter) did not differed between time points (p=0.589). 
(Table7.2) Binary analysis of clinical response into responders and non-responders 
showed that the difference between the two groups is statistically insignificant 
(p=0.387). 
Comparison of histopathological response between OG and TP group 
Chi-square test done to compare the histopathological responses has proved that 
there is no statistical difference in the histopathological response between the two 
treatment groups (p=1.000). (Table 5) 
Self-reported abstinence to tobacco habit 
Self-reported abstinence for tobacco habit at the end of three months for the OG 
and TP group revealed a quit rate of 45.5% and 50% respectively. In the OG group, 
9.1% (n=1) had no change in the tobacco habit, 45.5% (n=5) had partial change in the 
tobacco habit, 45.5% (n=5) had stopped use. Similarly in the TP group 10% (n=1) had 
no change in the tobacco habit, 40% (n=4) had partial change in the tobacco habit, 50% 
(n=5) had stopped use. The difference between the quit rate in OG group and TP group 
is statistically insignificant. (p=1.000). 
Drug compliance 
Among the 21 participants who completed the trial, 54.5% (n=6) in the OG 
group and 70% (n=7) in TP group were compliant with the trial drugs. The difference 
between the compliance of drugs between the OG and TP group is statistically 
insignificant (p=0.392). 
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Sub-group analyses in OG group 
           Binary analysis to assess the association between clinical response and quit 
status in the OG group has exposed that the difference between the clinical response 
and the quit status of the participants is statistically insignificant (p=0.567). Similarly 
the association between the clinical response and compliance of drug in the OG group 
is statistically insignificant (p=0.999). (Table 8, 9, 10, 11. Fig 4, 5). 
 Sub-group analyses in TP group 
  Binary analysis to assess the association between clinical response and quit 
status in the TP group has exposed that the difference between the clinical response 
and the quit status of the participants in the TP group is statistically insignificant 
(p=0.999). Similarly the association between the clinical response and compliance of 
drug in the TP group is statistically insignificant (p=0.999). (Table 8, 9, 10, 11. Fig 4,5)   
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RESULTS IN TABLES 
Table 3: Demographic characteristics of the participants 
Variables  
OG 
N (%) 
TP 
N (%) 
Total 
P -
value* 
Age   
Age ≤ 40 
Age ≥ 40 
9   (60) 
6   (40) 
8  (53.3) 
7  (46.7) 
17 (56.3)  
13 (43.7) 
1.000** 
Sex  
Male 
Female 
15 (100) 15 (100) 30 (100) 
- 
Marital status 
Unmarried 
Married 
2 (13.3) 
13(86.7) 
3   (20) 
12 (80) 
5   (16.7) 
25 (83.3) 
0.995** 
Socioeconomic 
status 
 
Upper class 
Upper-middle class 
Middle--lower-
middle class  
Lower--upper-lower 
class 
Lower class 
7  (46.7) 
4  (26.7) 
3  (20) 
1 (6.7) 
0 (0) 
12 (80) 
2  (13.3) 
1  (6.7) 
0 (0) 
0 (0) 
19 (63.3) 
6   (20) 
4   (13.3) 
1   (3.3) 
0 (0) 
0.288** 
Tobacco habit 
 
Smoking form 
Smokeless form 
Both 
6 (40) 
3 (20) 
6 (40) 
6 (40) 
6 (40) 
3 (20) 
12 (40) 
9   (30) 
9   (30) 
0.433** 
Alcohol habit 
 
Alcohol user 
Non-user-alcohol 
12 (80) 
3   (20) 
12 (80) 
3   (20) 
24 (80) 
6   (20) 
1.000** 
Type of 
leukoplakia 
Homogenous 
Non- Homogenous 
7 (46.7) 
8 (53.3) 
11(73.3) 
4 (26.7) 
18 (60) 
12 (40) 
0.136 
Multiple sites 
 
Yes 
No 
7 (46.7) 
8 (53.3) 
11(73.3) 
4 (26.7) 
18 (60) 
12 (40) 
0.136 
Site of lesion 
 
Buccal mucosa 
Tongue 
Palate 
Gum/Sulcus 
11(73.3) 
2(13.3) 
1(6.7) 
1(6.7) 
12 (80) 
2 (13.3)   
0 (0) 
1 (6.7) 
23 (76.7) 
4   (13.3) 
1   (3.3) 
2   (6.7) 
0.274** 
Classification  
by size 
 
<2 cm  
2-4 cm  
>4 cm 
Unspecified 
2 (13.3) 
6 (40) 
5 (33.3) 
2 (13.3) 
2 (13.3) 
8 (53.3) 
5 (33.3) 
0 (0) 
4   (13.3) 
14 (46.7) 
10 (33.3) 
2   (6.7) 
0.683** 
Histopathological 
evaluation 
Non-dysplastic 
Dysplastic 
10(66.7) 
5 (33.3) 
10(66.7) 
5(33.3) 
21 (70) 
09 (30) 
0.999 
 
OG- Oak gall group; TP-Triphala group; *- p < 0.005 –statistically significant;   
** Fisher exact tests done if expected cell frequency is less than five 
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Table 4: Comparison of clinical response between the Oak gall and                  
Triphala group 
Clinical response 
Group p value* 
OG TP Total 
 
 
 
0.228** 
N (%) N (%) N (%) 
Complete 0 (.0) 2 (20) 2(9.5) 
Partial 5 (45.5) 5 (50) 10 (47.6) 
Stable 6(54.5) 3(30) 9(42.9) 
Progressive 0(.0) 0(.0) 0(.0) 
Total 11(100) 10(100) 21(100) 
    
OG- Oak gall group; TP-Triphala group; *- p < 0.005 –statistically significant;   
** Fisher exact tests done if expected cell frequency is less than five 
 
 
Table 5: Comparison of histopathological response between Oak gall and 
Triphala group 
Histopathological 
responders 
Group 
p-value* OG TP Total 
N (% ) N (%) N (%) 
Responders 2 (25) 2 (28.6) 4 (26.7) 
1.000** Non-responders 6 (75) 5 (71.4) 11 (73.3) 
Total 8 (100) 7 (100) 15 (100) 
 
OG- Oak gall group; TP-Triphala group; *- p < 0.005 –statistically significant 
** Fisher exact tests done if expected cell frequency is less than five 
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Table 6: Independent samples t-Test to compare mean values between Oak gall 
and Triphala group 
Variables Group N Mean S.D t-Value p-value* 
Age 
OG 11 43.45 10.820 
0.222 0.826 
TP 10 42.50 8.593 
No of years of 
tobacco use 
OG 11 18.73 15.199 
0.010 0.992 
TP 10 18.67 10.062 
Baseline 
OG 11 395.45 285.078 
0.194 0.848 
TP 10 370.40 305.931 
6th week 
OG 11 213.00 147.694 
0.442 0.663 
TP 10 182.30 170.598 
3rd month 
OG 11 199.36 139.603 
0.782 0.444 
TP 10 146.00 172.569 
 
OG- Oak gall group; TP-Triphala group; *- p < 0.005 –statistically significant 
 
Table 7: Repeated measures ANOVA (General Linear Model) to compare the 
mean values within and between groups over the time period 
                                        Table 6.1: Descriptive statistics 
Variable Group N Mean 
Standard 
Deviation 
Baseline 
OG 11 395.45 285.078 
TP 10 370.40 305.931 
Total 21 383.52 287.952 
6th week 
OG 11 213.00 147.694 
TP 10 182.30 170.598 
Total 21 198.38 155.725 
3rd month 
OG 11 199.36 139.603 
TP 10 134.40 172.435 
Total 21 168.43 155.660 
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Table 7.1: Tests of Within-Subjects Effects 
Source df Mean Square F-value p-Value 
Values Greenhouse-Geisser correction 1.029 556004.409 10.881 0.003 
Error Greenhouse-Geisser correction 19.559 51096.355 - - 
Table 7.2: Tests of Between-Subjects Effects 
Source df Mean Square F-value P-Value 
Group 1 25444.710 .302 0.589 
Error 19 84117.483 - - 
 
OG- Oak gall group; TP-Triphala group; *- p < 0.005 –statistically significant 
 
Table 8: comparison of proportions between the clinical response and quit status 
at the end of three months within and between the groups 
Group 
Clinical 
responders 
Quit status 3 months 
p-value* Quit Not quit Total 
N (%) N (%) N (%) 
OG 
Responder 3 (60) 2 (33.3) 5 (45.5) 
0.567** 
 
Non- responders 2 (40) 4 (66.7) 6 (54.5) 
Total 5(100) 6 (100) 11(100) 
TP 
Responder 4 (80) 3 (60) 7(70) 
0.999** 
 
Non- responders 1 (20) 2 (40) 3 (30) 
Total 5 (100) 5 (100) 10 (100) 
Total 
Responder 7 (70.0) 5(45.5) 12(57.1) 
0.387** Non- responder 3 (30.0) 6 (54.5) 9 (42.9) 
Total 10 (100) 11(100) 21(100) 
 
OG- Oak gall group; TP-Triphala group; *- p < 0.005 –statistically significant 
** Fisher exact tests done if expected cell frequency is less than five 
 
 
 
Results 
41 
 
Table 9: Comparison of proportions between the clinical response and 
compliance at the end of three months within and between the groups 
Group 
Clinical 
responders 
Compliance 3 months 
p- value* Compliant Non-compliant Total 
N (%) N (%) N (%) 
OG 
Responder 3 (50) 2(40) 5 (45.5) 
0.999** 
 
Non- responder 3 (50) 3 (60) 6 (54.5) 
Total 6 (100) 5 (100) 11 (100) 
TP 
Responder 5 (71.4) 2 (66.7) 7 (70.0) 
0.999** 
 
Non- responder 2 (28.6) 1 (33.3) 3 (30) 
Total 7 (100) 3 (100) 10 (100) 
Total 
Responder 8 (61.5) 4 (50) 1 2 (57.1) 
0.673** Non- responder 5 (38.5) 4 (50) 9 (42.9) 
Total 13 (100) 8 (100) 21 (100) 
 
OG- Oak gall group; TP-Triphala group; *- p < 0.005 –statistically significant 
** Fisher exact tests done if expected cell frequency is less than five 
 
Table 10: Comparison of proportions between the histopathological response 
and quit status at the end of three months within and between the groups 
Group 
Histopathological 
responders 
Quit status 3 months 
p- value* Quit Not quit Total 
N (%) N (%) N (%) 
OG 
Responder 1 (33.3) 1(20) 2 (25 
0.999** 
 
Non- responder 2 (66.7) 4 (80) 6 (75) 
Total 3 (100) 5 (100) 8 (100) 
TP 
Responder 2(50) 0 (.0) 2(28.6) 
0.429** 
 
Non -responder 2 (50) 3 (100) 5 (71.4) 
Total 4 (100) 3 (100) 7 (100) 
Total 
Responder 3 (42.9) 1 (12.5) 4 (26.7) 
0.282** Non- responder 4 (57.1) 7 (87.5) 11 (73.3) 
Total 7 (100) 8 (100) 15 (100) 
 
OG- Oak gall group; TP-Triphala group; *- p < 0.005 –statistically significant 
** Fisher exact tests done if expected cell frequency is less than five 
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Table 11: Comparison of proportions between the histopathological response 
and compliance within and between the groups 
Group 
Histopathological 
responders 
Compliance 
p-value* Quit Not quit Total 
N (%) N (%) N (%) 
OG 
Responder 2(40) 0 (.0) 2 (25) 0.464** 
 
Non -responder 3(60) 3 (100) 6 (75) 
Total 5 (100) 3(100) 8 (100) 
TP 
Responder 2 (33.3) 0(.0) 2 (28.6) 
0.999** 
 
Non- responder 4 (66.7) 1 (100) 5 (71.4) 
Total 6 (100) 1(100) 7 (100) 
Total 
Responder 4 (36.4) 0 (.0) 4 (26.7 
0.516** Non- responder 7 (63.6) 4(100) 11(73.3) 
Total 11(100) 4(100) 15 (100) 
 
OG- Oak gall group; TP-Triphala group; *- p < 0.005 –statistically significant 
** Fisher exact tests done if expected cell frequency is less than five 
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FIGURE 2 
 
 
FIGURE 3 
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FIGURE 4 
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PHOTOGRAPH 7: COMPARISON OF BASELINE AND THIRD MONTH 
CLINICAL FINDINGS OF SUBJECTS IN OAK GALL GROUP 
                 PRE TREATMENT                                 POST-TREATMENT  
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PHOTOGRAPHS 8: COMPARISON OF BASELINE AND THIRD MONTH 
CLINICAL FINDINGS OF SUBJECTS IN TRIPHALA GROUP 
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PHOTOMICROGRAPH 9: HISTOPATHOLOGICAL COMPARISON OF PRE AND 
POST INTERVENTION AMONG SUBJECTS IN THE OAK GALL GROUP 
                         PRE-TREATMENT                                                                                                  POST TREATMENT 
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epithelium 
9.11: Orthokeratosis, bulbous 
rete pegs, Inflammatory cell 
infiltration 
9.12: Hyperplastic, bulbous rete 
pegs, hyper keratinized, 
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PHOTOMICROGRAPH 10: HISTOPATHOLOGICAL COMPARISON OF PRE AND 
POST INTERVENTION AMONG SUBJECTS IN THE TRIPHALA GROUP 
 
                PRE-TREATMENT                                                                                                  POST TREATMENT 
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DISCUSSION 
Studies in the literature have shown various surgical and non-surgical methods 
for the treatment of oral leukoplakia.42   Chemo preventive measures for treatment of 
leukoplakia has shown high relapse rates and adverse effects on long term use which 
was emphasized in a recent meta-analysis in the Cochrane review.29 As the malignant 
transformation rates of oral leukoplakia range from 0.13 to 17.5% 70 and treatment of 
oral leukoplakia warrants long term supplementation, indigenous plant product can 
serve as a simple, less toxic, culturally  acceptable modality for the non-surgical 
management of leukoplakia.  
Tobacco consumption exposes the oral epithelium to toxic oxygen and nitrogen 
free radicals that can affect host antioxidant defence mechanisms.71 Anti-oxidants have 
a very vital role against the deleterious action of these free radicals. Oak gall and 
Triphala is extensively reviewed for their anti-oxidant properties.34-41 To the best of our 
knowledge there are no studies carried out to evaluate the effectiveness of Oak gall oil 
and Triphala oil as an adjuvant to tobacco cessation in the reversal of oral leukoplakia. 
Topical form of application used in this study has a several advantages over 
systemic administration. Topical administration can be applied directly over the lesion, 
has a localized action and less severe adverse effects when administered in higher doses 
when compared to systemic administration.72 
There were thirty participants randomized into two groups with an allocation 
ratio of 1:1 with 15 subjects in OG group and 15 subjects in TP group. A total number 
of 21 participants completed the trial resulting in a dropout rate of 26.7% (n=4) in the 
OG group and 33.3% (n=5) in the TP group. 
Demographic data revealed that there were 30 male participants reported in this 
study with no female participant. This may be attributed to the high prevalence of 
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leukoplakia among males which was consistent with that of similar previous 
studies.58,68,69,73 Smoking form (40 %) was found to be the predominant form of tobacco 
associated with leukoplakia in this study which was similar to that of previous studies.73 
There is a statistically significant difference  (p=0.028) in the level of dependence for 
smoking form of tobacco  (Fagerstrom scale) between the OG group and TP group. 
Buccal mucosa (76.7%) was found to be the most common site of lesion in this study 
which was similar to that of the previous studies on oral leukoplakia.74 It is usually 
assumed that reversal of any oral lesion may also be influenced by the size of the lesion. 
However the present study has reported that there is no statistical difference in the size 
of the lesion between the treatment groups. (p= 0.683) 
The primary endpoints used in this trial were the clinical measurement of the 
lesion and histopathological evaluation to assess the reversal of leukoplakia. 
The clinical response rate (Complete response + Partial response) for OG group 
was found to be 45.5%.and clinical response rate (Complete response + Partial 
response) for TP group was found to be 70%. This can be due to the better compliance 
of drug seen in the TP group. There was significant decrease in the mean size of the 
lesion over the time period in both the OG and TP group which is statistically significant 
(p=0.003) but the difference in the clinical response between the groups is statistically 
insignificant (p=0.444). 
 The histopathological response rate for OG group and TP group was found to 
be 25% and 25.7% respectively. Histopathological evaluation has shown reversal of 
leukoplakia from mild dysplasia to hyperplasia in two participants in the OG group. 
Among the two participant one had completely quit the habit and the other had only 
reduced the number of tobacco use. Similarly there was reversal of leukoplakia from 
mild dysplasia to hyperplasia in two participants of TP group. Both the participants had 
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quit the habit of tobacco in the Triphala group. However there was progression of 
disease in one participant in Triphala group. The quit habit of the participant revealed 
partial reduction in the use of tobacco. All the participants who had enrolled for this 
trial were strongly recommended for a continuous follow up till one year even if there 
was complete resolution of the lesion. Participant who showed progression of disease 
histopathologically at the end of three months was referred for the routine treatment 
given for leukoplakia. 
To the best of our knowledge there were no in-vivo studies on Oak gall 
documented in the management of oral leukoplakia. However , A study by Deshpande 
et al., 2014 on the reversal of aceto-white lesions among 34 teenagers in Indian 
population by Triphala rinse revealed that histological findings after 9 month use of 
Triphala mouth rinse has shown no changes in cells in 85.2%, hyperkeratinisation in 
7.4%, hyperkeratinisation and spongiosis in 3.7%, mild pleomorphism in 3.7% patient. 
Comparative evaluation of the lesion from 0-9 month showed statistically significance 
(P < 0.01).35 
The present study has shown a significant reversal of leukoplakia in both the 
OG and TP group clinically by measurement of the lesion but not histopathologically. 
This may be attributed to short duration of follow up seen in this trial. Histopathological 
evaluation has its own demerits. They are more prone to high inter-observer variability 
in interpretation of the findings and further the presence of technical artifacts while 
obtaining the biopsy specimen cannot be underestimated.75 This was minimized by 
using a predefined grading of dysplasia to obtain consensus among the oral pathologists 
who evaluated the lesion histopathologically. Further the effect of “field cancerization” 
should be taken into consideration cautiously76 as the worst site may have been taken 
up for post intervention biopsy at the end of three month but have not been included in 
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the pre- intervention biopsy. This effect of field cancerization may underestimate the 
effectiveness of the trial drugs. This was overcome by toluidine blue staining of the 
lesion to screen out dysplastic changes and to mark the site of biopsy.  
Similarly clinical measurement of the oral mucosal lesions has its own 
drawbacks such as elasticity of the oral mucosa, ill-defined anatomic land marks for 
measurement, complexity in the size and shape of the lesion, involvement of multiple 
sites. These were overruled in this study by selecting a primary index lesion for 
measurement at various time periods, with three consecutive measurements which were 
taken by two examiners separately and the average of them was taken as the 
measurement of the lesion. This technical flaws which may arise when using clinical 
and histopathological evaluation as a primary outcome measure should be taken into 
consideration in future trials and the use of surrogate outcome measures such as 
molecular biological markers as end point assessment should be studied in detail. 
Tobacco cessation counselling was given to both the groups in a phased and 
structured manner. The quit rate assessed in this study was 45.5% in OG group and 50% 
for TP group. Similarly the compliance of the drug in the TP group (70%) was 
comparatively better than OG group (54.5%). This may have contributed for a better 
clinical response rate in the TP group than in the OG group. However the different in 
the quit status (p=1.000) and the compliance of drugs ((p=0.392) between the groups is 
not statistically significant. 
There were no adverse effects reported in the OG and TP group during the trial 
period. The dosage of oil used in this study was well tolerated by the participants and 
two of the participants in the OG group and three in the TP group reported subjective 
improvement in their oral well-being (reduction in pain, burning sensation in the oral 
mucosa). It is to be noted that 6ml/day dose was used in this study based on the 
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previously established tolerance dose and not the efficacy dose. Thus, if the compliance 
in clinical practice proves to be an issue, it could be of value to determine efficacy dose 
of both Oak gall oil and Triphala oil.  Five of the study participants reported that a gel 
form of medication in a tube could have been better to be used conveniently at work 
hours which might have increased the compliance of the drugs used.   
The strength of the study was the stringent methodology followed throughout 
the trial. Selection bias was addressed by strict inclusion and exclusion criteria, 
randomization of the participants and allocation concealment. Investigator bias was 
avoided by blinding the investigator about the treatment groups, Ascertainment bias 
was avoided by blinding the participants. 
It is important to bring to note that there are few limitations in the present study. 
The first limitation in this study was the loss to follow up seen in significant number of 
the participants in both the groups (4 in OG group and 5 in TP group).The major reasons 
given to loss to follow up in this study was the fear, subjective well-being  regarding 
the disease and personal reasons addressed by the participants. The second limitation 
was the duration of follow up. Since oral leukoplakia follows a long clinical course 
adequate period of follow up are essential to evaluate the durability of response and 
relapse rates attributed to Oak gall and Triphala oil. Long term follow up trials are 
needed to evaluate the durability of response and relapse rates attributed to Oak gall 
and Triphala oil. The third limitation in this trial was small sample size which may 
hinder the generalizability of the results. As the study was carried out as a part of post-
graduate curriculum with short recruitment period, appropriate sample size to 
generalize the results cannot be achieved. As the prevalence of leukoplakia is low, large 
multi-centred trial would be recommended to fulfill the recruitment for leukoplakia 
studies.  This suggestions were similar to that of a study on the feasibility of recruitment 
Discussion 
62 
 
to an oral dysplasia trial in United Kingdom. The study has expressed difficulties in 
conducting a clinical trial on oral dysplasia in a single institution and this was attributed 
to the low incidence of oral dysplasias in United Kingdom.77  
The anti-oxidant properties of Oak gall and Triphala is extensively studied and 
reviewed.34-41 However the exact pathway of action of Oak gall oil and Triphala oil as 
an anti-oxidant/anti-cancer drug is still unclear. The mechanism of action of Oak gall 
oil and Triphala oil against the reactive oxygen species and reactive nitrogen species 
generating free radicals resulting in malignant transformation of oral leukoplakia 
should be thoroughly studied to introduce targeted therapies against oral leukoplakia. 
Tobacco cessation may have a confounding effect on the effectiveness of the trial drugs. 
Hence well controlled clinical trials, with long term follow up with definitive end point 
assessment is highly recommended in future trials. 
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SUMMARY AND CONCLUSION 
The present study has shown that indigenous plant products such as Oak gall 
and Triphala oil can be used as an adjuvant in the management of oral leukoplakia. 
In this trial, the clinical response rate was 45.5% for the Oak gall group and 70% 
for the Triphala group. There was a statistically significant improvement in the clinical 
measurement of the lesion over the tested time period within the groups. However, there 
was no significant difference between the Oak gall group and Triphala group in the 
reversal of oral leukoplakia both clinically or histopathologically.  
These findings suggest that both Oak gall oil and Triphala oil may be used as 
an adjuvant to tobacco cessation counselling in the reversal of oral leukoplakia. 
However, the durability of response shown by the trial drugs needs to be studied. The 
dosage of drugs used in this trial is based on the tolerated dose from previous studies 
but not on the efficacy dose. Therefore, clinical trials with precisely defined end-points, 
long term follow up, different dosages of trial drugs and the required larger samples are 
recommended in near future.  
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இணைப்பு – I 
Muha;r;rp gw;wpa jfty;  
jkpH;ehL muR gy; kUj;Jtf; fy;Yhhp kw;Wk; kUj;Jtkid-brd;id 3 
rKjha gy; ghJfhg;g[ gphpt[ 
வெண்படல்  
வெண்படல்  
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,e;j Muha;r;rp ed;F gapw;rp bgw;w gy; 
kUj;Jtuhy; mspf;fgLfpwJ. Mjyhy; ve;j tpj ghjpg;g[k; Vw;gl tha;g;g[ ,y;iy.
.jfty; ,ufrpak;                                                      
      fye;Jf;bfhs;Sk; neha}spfSf;F thpir vz; jug;gLk; kw;Wk; mth;fspd; Fwpg;g[fs; 
Muha;r;rp Koa[k; tiu gpwu; mwpahtz;zk; ,ufrpakhf ghJfhf;fg;gLk;. mij btspapLk; 
neuj;jpy; ve;j nehahspapd; jdp milahs';fSk; btspapl glkhl;lhJ. 
jdpr;irapy;yhj g';nfw;wy; 
      ,e;j Muha;r;rpapy; g';F bgWtJ c';fspd; jdpg;gl;l KothFk;. ,J nehahspfs; 
jhdhfnt g';fspf;Fk; gl;rj;jpy;  gazg;gpo jug;glhJ. ,e;j Muha;r;rpapypUe;J eP';fs; 
vg;bghGJ ntz;LkhdhYk; tpyfpf; bfhs;syhk;. ,J c';fSf;nfh my;yJ 
Muha;r;rpahsUf;nfh ve;jtpj ghjpg;g[k; Vw;gLj;jhJ vd;gij  bjhpag;gLj;Jfpnwhk;. 
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Muha;r;rpahsh; ifbahg;gk;         ifbahg;gk;  ifnuif                            
                                                                                  
  
 பங்கேற்பாளர்/பபற்க ார்/பhதுோவலர் 
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ANNEXURE –II 
TAMILNADU GOVT. DENTAL COLLEGE AND HOSPITAL CHENNAI -3 
DEPARTMENT OF PUBLIC HEALTH DENTISTRY 
INFORMATION SHEET 
INTRODUCTION OF THE CHIEF INVESTIGATOR 
 I, Dr.S.Sharmila doing II year post graduate student in the Department of 
Public Health Dentistry in Tamil Nadu Government Dental College and Hospital, 
Chennai. As dissertation is my part my PG curriculum, I would like to do my 
dissertation regarding “Comparison of the effectiveness of Oak gall oil with 
Triphala oil as an adjuvant in the reversal of oral leukoplakia  –A double blinded 
randomized clinical trial.” All this work will be carried out under the guidance of 
my Professor and Head of the Department Dr. M.B. Aswath Narayanan B.Sc, MDS. 
STUDY TITLE              
Comparison of the effectiveness of Oak gall oil with Triphala oil as an adjuvant 
in the reversal of oral leukoplakia –A double blinded randomized clinical trial  
1. Nature of study 
 The aim of the present study is to compare the effectiveness of Oak gall oil 
with Triphala oil as an adjuvant in the reversal of oral leukoplakia –A double 
blinded randomized clinical trial  
2. Purpose of study 
Oral cancer is the fifteenth most common cancer world-wide. In India Oral 
cancer ranks first among male and fourth among females. Oral cancer may develop 
from oral precancerous lesions/conditions or directly from a normal mucosa. It been 
reported to show a significant tendency to malignant transformation from 0.13 to 6%, 
and rising to 14% or higher when dysplasia is present. Tobacco and alcohol use has 
been estimated to account for 50% of squamous cell carcinoma and 30% of world -
wide cancer burden. Early detection and management of oral pre-malignant lesions is 
important to improve the survival rate and quality of life. The World Health 
Organization estimates that 80% of the world's inhabitants rely mainly on traditional 
medicines for their health care. Intervention of premalignant lesions/conditions at an 
earlier stage by cost effective methods such as tobacco cessation counselling and by 
use of traditional medicines will not only reduce the economic burden of treating the 
disease but also will substantially increase the life span and thereby the quality of life 
of the individual and therefore taken for this study. 
3. Procedure and duration of study  
We are inviting people with the white/red lesions and who are tobacco users of 
any kind and who attend to the hospital to participate in the research on the new 
topical application for pre-cancerous lesion. This research will involve a topical 
application of the drug in your mouth for a period of three weeks as well as five 
follow-up visits to the hospital. The topical applications we are testing in this research 
is called oak gall oil and triphala oil. It has been tested before with people for various 
ailments. We now want to test the drug on people who have oral precancerous lesions. 
You should know that the side effects, or problems in using this oil is very minimal or  
 


 
 
none as it is a naturally obtained herbs which has been used in ancient medicine and 
has been mentioned in the literature also. Because we do not know if the oak gall oil 
for topical application is better than the Triphala oil, we need to compare the two. To 
do this, we will put people taking part in this research into two groups which are 
selected by random chance. Participants in one group will be given the oak gall oil 
while participants in the other group will be given Triphala oil. After test dose under 
local anesthesia, we will take a small amount of your tissue measuring 6 mm from the 
lesion by punch biopsy to grade and confirm the level of dysplasia. 
 A punch biopsy is a painless invasive procedure done under local anesthesia 
to check the cell level changes occurring in the specified site. This will be done prior 
to the study and at the end of the trial to evaluate the clinical outcome. The research 
takes place over a period of three months in total. During that time, it will be 
necessary for you to come to the hospital every 15th day, the date and time of which 
will be mentioned and will be given to you in an outpatient card. We would like to 
meet with you three months after your last clinic visit for a final check-up. In total, 
you will be asked to come 5 times to the clinic in 3 months. A periodic recall visit 
every 3 months after the study for one year to the institution for review is necessary. 
A tobacco cessation counselling will be given to you depicting the ill effects of 
tobacco, how to quit from the habit, benefits of quiting. The counselling comprises of 
4 session (first day, 15th day, 1 month and 6th week) coinciding with the dates of your 
drug review. The investigator will be looking after you and the other participants very 
carefully during the study. Photographs of your lesion will be taken at every visit to 
assess the level of reversal of the lesion. If there is anything you are concerned about 
or that is bothering you about the research please talk to me or one of the other 
researchers.  
4. Risks 
As the trial drugs are obtained from naturally occurring edible plants and has 
been abundantly used in the Indian medicinal literature the possibility of adverse 
effects reported with the use of the same is considered to be less. In case if any 
adverse event occurs you will be treated and will be given the standard drug regimen 
for the disease. This trial is carried under the guidance of trained experts and therefore 
the possibility of adverse events are less. 
5. Benefits 
Oak gall and Triphala are naturally obtained herbs and less toxic compared to 
chemotherapeutic drugs and easily available. Your participation in this study is likely 
to help us find the answer to the research question. There may not be any benefit to 
the society at this stage of the research, but future generations are likely to benefit. 
 
6. Confidentiality 
  The data collected from the participants are maintained confidential by the 
investigator. A code is assigned to each participant immediately after recruitment to 
ensure that their identity is not revealed throughout the study.  
 7. Voluntary participation 


 Taking part in the study is voluntary. You are free to decide whether to 
participate in the study or to withdraw at any time; your decision will not result in any 
loss of benefits to which you are otherwise entitled. 
 
CONTACT DETAILS  
Contacts details of The Principal investigator: 
       Dr.S.Sharmila, 
       IInd year Post Graduate, 
       Room No- 4, Department of Public Health Dentistry, 
       Tamilnadu Govt Dental College & Hospital, 
       No -2, Frazer bridge road, 
       Chennai-600003. 
       Phone number: 9791979003 
 
Contact details regarding rights of the participant. 
      The Chairperson,  
      Institutional Ethics Committee, 
      Tamilnadu Govt Dental College & Hospital, 
      Chennai. 
      Phone number:  
 
            
Name of Participant:   
                                               
Investigator   :  
      
Date:                                                                            Signature/Thumb impression of 
                               Parent/Guardian                 
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 இணைப்பு –III 
 
  Muha@r@rpahsh;: மரு.r.rh;kpsh               Guide: மரு. ம.பா. அஸ்வத் நாராயணன்   
       
jkpH;ehL muR gy; kUj;Jtf; fy;Yhhp kw;Wk; kUj;Jtkid-brd;id 3 
rKjha gy; ghJfhg;g[ gphpt[ 
Muha@r@rp xg@g[jy@ gotk@ 
Muha@r@rp jiyg@g[  : 
d வவண்படல்     
 
 
bgau; :jpU_jpUkjp........................................_                           g[w nehahspapd; vz; 
............................... 
Kftup:     :.............................................................                              ghypdk:   Mz;_ bgz; 
        ..............................................................                             taJ:          
        .............................................................               
ehd; ..........................................._  vd@Dila Raepidt[lDk; kw;Wk; KGRje;jpuj;JlDk; vd;id 
,k;kUj;Jt Muha@r@rpapy@ nru@j@Jf@ bfhs@s xg@g[jy@ mspf@fpnwd@.  
1. ,e@j Muha@r@rpapd@ nehf@fk@ kUj;JtKiwfs@ kw;Wk; gupnrhjid Kiwfs; Fwpj;j 
tpsf@f'@fs@ midj@Jk@ vdf@F jpUg@@jp jUk@ tifapy@ mspf@fg@gl@ld. 
2. ,e;j Muha;r;rpf;fhf vdJ tha; KG ghpnrhjid bra;ag;gLk; vd;gij mwpfpnwd;. 
3. ,e;j Muha;r;rpf;F njitahd KGikahd ghpnrhjidf;F xj;JiHf;f rk;kjpf;fpnwd.; 
 
4. ehd; Vw;fdnt cl@bfhz@l kw;Wk; cl@bfhs@fpw kUe@Jfisg@ gw;wpa 
tptu'@fisMuha@r@rpahsuplk@ bjuptpj@Js@nsd@. 
5. kUj;Jthpd; Muha;r;rpw;F njitg;gLk;bghGJ kPz;Lk; kUj;Jt Ma;tpw;F fz;og;ghf 
Muha;r;rpahshplk; tu   rk;kjpf;fpnwd;. 
6. ve@j xU epiyapYk@ ehd@ ,e@j Muha@r@rpapypUe@J tpyFtjw;Fk@ my@yJ kUj;Jt 
Muha@r@rpahsUf@F vd@id tpyf@Ftjw;Fk@ KG cupik  ,Ug@gjhft[k@ mwpfpnwd; 
7. vd; kUj;Jtf; Fwpg;ngLfis ,e@j Muha@r@rpapy@ gad@gLj@jpf@bfhs@s rk@kjpf@fpnwd@. ,e@j 
Muha@r@rp ikaKk@ Muha@r@rpahsUk@ vd@Dila tptu'@fs@ midj@ija[k; ,ufrpakhf 
itg@gjhf mwpfpnwd;. 
8. vdf;F gof;f bjhpahjjhy;/ nkny cs;s midj;ija[k; Twf;nfl;nld;.  
 
 
    
bgau;                               ifbahg@gk@_ ifnuif            njjp 
 
    
 
 
Muha@r@rpahsh;                                                      njjp 
 
thpir vz; :  
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ANNEXURE IV 
TAMILNADU GOVT. DENTAL COLLEGE & HOSPITAL CHENNAI -3 
DEPT. OF PUBLIC HEALTH DENTISTRY 
Investigator: Dr. S.Sharmila                   Guide: Dr. M.B. Aswath Narayanan, B.sc, MDS 
 
                                    INFORMED CONSENT FORM 
Study title: Comparison of the effectiveness of Oak gall oil withTriphala oil as an 
adjuvant in the reversal of oral leukoplakia – A double blinded randomized clinical 
trial 
Name:     Mr/Ms ______________________________ 
Address:    ____________________________________               SEX   : Male /Female 
                  ____________________________________               AGE   :            Years 
                  ____________________________________ 
 
I, ________________________, exercising my free power of choice, hereby give my 
consent to be included in the study. 
 
I agree to the following: 
 
1. I have been informed to my satisfaction about the purpose of the study and study 
procedures. 
2. I agree to have a full mouth examination for the purpose of this research 
3. I agree to co-operate fully for complete examination and I am informed that oral 
punch biopsy and photographs of the oral lesion will be taken during the study. 
4. I have informed to the investigator about the details of the medications I had taken 
or being taken 
5. I agree to revisit for the purpose of this research if needed in in the future 
6. I understand that I have rights to withdraw from the study and also that the 
investigator has the right to exclude me from the research at any point of time. 
7. I hereby give permission to use my medical records for research purpose. I am told 
that the investigating doctor and the institution will keep my identity confidential. 
8. As I am unable to read and write the following points are read and explained to me 
very clearly 
 
Name of Participant: 
Investigator   : 
Date:                                                      Signature/Thumb impression  
 
 
S.NO: 
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ANNEXURE V 
PHOTOGRAPH 11 
ARMAMENTARIUM USED FOR CLINICAL EXAMINATION 
Armamentarium for clinical evaluation: From the left -Disposable gloves, Head 
cap, Mouth mask, Goggles, Mouth mirror, Explorer, William’s periodontal probe, 
Tweezers, Metallic scale, Metallic divider, Cheek retractor, Cotton holder, Stainless 
steel rectangular tray 
 
PHOTOGRAPH 12 
  
ARMAMENTARIUM FOR TOLUDINE BLUE STAINING 
 
Armamentarium for toludine blue staining: from the left-mouth mirror, tweezer, 
measuring cup, toludine blue solution, cheek retractor, dappen dish with cotton pellets 
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PHOTOGRAPH 13 
ARMAMENTARIUM FOR ORAL PUNCH BIOPSY USED AT 
DEPARTMENT OF ORAL SURGERY  
 
 
 
Armamentarium for oral punch biopsy shown from the left upper corner: tongue 
depressor, 0.9% normal saline, povidone  iodine solution, oral biopsy punch(6mm), 
gauze strips, suction tip, suture needle, needle holder, artery forceps, mouth mirror, 
straight scissors, mosquito artery forceps, curved scissors, tissue holder, 2% lignocaine 
solution loaded in 5ml syringe  
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PHOTOGRAPH 13.1: ORAL PUNCH BIOPSY PROCEDURE 
 
 
 
  
 
 
 
 
Photograph 13.1.1Site of the lesion 
 
 
  
 
 
 
 
 
 
Photograph 13.1.2: Insertion of oral biopsy punch under local anesthesia 
 
 
 
 
 
 
 
 
 
Photograph 13.1.3: Site of the lesion immediately after biopsy and obtaining 
haemostasis 
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ANNEXURE VI 
TAMILNADU GOVERNMENT DENTAL COLLEGE AND HOSPITAL 
DEPARTMENT OF PUBLIC HEALTH DENTISTRY 
COMPARISON OF THE EFFECTIVENESS OF OAK GALL OIL WITH TRIPHALA OIL AS AN 
ADJUVANT IN THE REVERSAL OF ORAL LEUKOPLAKIA   –A DOUBLE BLINDED 
RANDOMIZED CLINICAL TRIAL 
Investigator: Dr. S.Sharmila                   Guide: Dr. M.B. Aswath Narayanan, B.sc, MDS 
Case record form 
 Date:                                                                                                        S.No: 
 OP.No:   
Demographic data 
1. Name      : Mr./ Ms.  
2. Age (as on last Birthday)              :         Years 
3. Sex                  : Male/ Female 
4. Date of Birth     : 
5. Place of Birth    : 
6. Religion                : 
7. Socioeconomic status             :  
Kuppuswamy socio economic status scale (updated for July 2016) 
S.N (A) EDUCATION  SCORE 
1  PROFESSION OR HONOURS  7 
2 GRADUATE OR POSTGRADUATE  6 
3 INTERMEDIATE OR POST HIGH SCHOOL DIPLOMA  5 
4 HIGH SCHOOL CERTIFICATE  4 
5 MIDDLE SCHOOL CERTIFICATE  3 
6 PRIMARY SCHOOL CERTIFICATE  2 
7 ILLITERATE  1 
S.N (B) OCCUPATION  SCORE 
1 PROFESSION  10 
2 SEMI-PROFESSION  6 
3 CLERICAL,SHOP OWNER,FARMER  5 
4 SKILLED WORKER  4 
5 SEMI-SKILLED WORKER  3 
6 UN SKILLED WORKER  2 
7 UNEMPLOYED  1 
S.N LATEST REVISION IN Rs/MONTH (CPI -269 )  SCORE 
1 >= 41,448  12 
2 20,744 – 41,447  10 
3 15,558 – 20,743  6 
4 10,372 – 15,557  4 
5 6223 – 10,371  3 
6 2095 – 6222  2 
7 <=2094  1 
8 PER CAPITA INCOME  
  TOTAL  
 1) 26-29 ----upper class (i)                                                         2) 16-25----upper-middle class (ii) 
 3) 11-15 middle-----lower-middle class (iii)                              4) 5-10 lower----upper-lower class (iv)          
 5) <5 ------lower class (v) 
      
8. Permanent Address   :  
9. Phone number               : 
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10. Past medical history        : hypertension/coronary heart disease/congenital heart 
disease/diabetes/jaundice/asthma/epilepsy/drug allergy/hospitalization 
11. Past dental history                      :                    
12. Personal history                                 
Marital status: 
No of children: 
13. Family history                                    
Father: 
Mother: 
No and age of siblings: 
Spouse: 
Children: 
14. Extra oral examination: 
Facial Symmetry:  
Skin 
Nose 
Lip  
Cervical lymphadenopathy:  
15. Intraoral examination 
 Soft tissue examination 
Assessment of the lesion: 
Site: 
Size: 
Shape: 
Consistency: 
Surface texture:  
Induration: 
Ulceration:  
Hard tissue examination: 
Grossly decayed teeth: 
Sharp tooth:   
Under filled/overhanging restoration :  
Ill-fitting dentures: 
Others: 
16. Provisional diagnosis: 
 
17. Investigations: 
 
18. Final diagnosis: 
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19. Tobacco Habits   
Habit Type Age of 
onset 
No of 
years of 
regular 
tobacco 
use 
Sachet/cigarette 
years (No of 
ciggs,biddis/sachet
s used per day x 
No of years of 
regular tobacco 
used 
Average 
number 
of 
cigarettes/ 
sachets 
amount of 
tobacco 
chewed 
per day in 
the last 
one 
month 
Smoking 
form of 
Tobacco 
cigarette,beedi,chutta, 
chevroots,hookli, hooka, 
dhumti,  chillum, Reverse 
smoking 
    
Smokeless 
form of 
Tobacco 
Betelquid,Manipuri 
tobacco, pan masala, 
mawa, gutka, khaini, 
Mishri, snuf 
    
20. Expenses per month on tobacco Rs: 
21. FAGERSTROM TEST FOR NICOTINE DEPENDENCE (FTND) FOR SMOKERS 
1. How soon after you wake up do you have your first cigarette? 
A. Within 5 minutes (3) 
B. 6-30 minutes (2) 
C. 31-60 minutes (1) 
D. After 60 minutes (0) 
2. Do you find it difficult to refrain from smoking in places where it is forbidden? 
A. Yes (1) 
B. No (0) 
3. Which cigarette would you hate most to give up? 
A. The first one in the morning (1) 
B. All others (0) 
4. How many cigarettes per day do you smoke? 
A. 10 or fewer (0) 
B. 11-20 (1) 
C. 21-30 (2) 
D. 31 or more (3) 
5. Do you smoke more frequently during the first hours after waking than during the 
rest of the day? 
A. Yes (1) 
B. No (0) 
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6. Do you smoke even if you are so ill that you are in bed most of the day? 
A. Yes (1) 
B. No (0) 
TOTAL: ___________________ 
0-2:         Very low dependence 
3-5:         Medium dependence 
6-7:         High dependence 
Above 8: Very high dependence 
22. FAGERSTROM TEST FOR NICOTINE DEPENDENCE-SMOKELESS TOBACCO (FTND-ST) 
1. How soon after you wake up do you have your first dip? 
A. Within 5 minutes (3) 
B. 6-30 minutes (2) 
C. 31-60 minutes (1) 
D. After 60 minutes (0) 
2. Do you chew if you are so ill that you are in bed most of the day? 
A. Yes (1) 
B. No (0) 
3. How many times do you use it per week? 
A. More than 4 times (2) 
B. More than 2 times (1) 
C. Less than 2 times (0) 
4. How often do you intentionally swallow tobacco juice? 
A. Always (2) 
B. Sometimes (1) 
C. Never (0) 
5. Do you keep a dip or chew in your mouth almost all the time? 
A. Yes (1) 
B.  No (0) 
6. Do you experience strong craving for a dip or chew when you go for more than two 
hours without one? 
A. Yes (1) 
B.  No (0) 
7. On average, how many minute do you keep a fresh dip or chew in your mouth?  
A. More than 30 minutes (3) 
B. 20 -30 minutes (2)  
C. 10-19 minutes (1) 
8. What is the length of your dipping day (total hours from first dip/chew in a.m. to last 
dip/chew in p.m.) 
A. More than 15 hours (2) 
B. More than 14.5 hours (1) 
C. Less than 14.5 hours (0) 
9. On an average, how many dips/chew do you take each day? 
A. > 15 times (3) 
B. 10-15 times (2) 
C. 1-9 times (1) 
TOTAL: ___________________ 
0-4: Very low dependence 
4-8: Medium dependence 
9-12: High dependence 
Above 12: Very high dependence 
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23. No of previous attempts at quitting which lasted for at least one month________ 
24. Alcohol use 1. Yes 2. No; 
If yes, Alcohol use in last one year (pattern) ____________________________ 
* pattern of use in the past one year 1.Daily drinking 2. Regular drinking ( 3 or more times / 
week)       3.Social drinking (<3 times week) 4. None 
25. Average amounts per drinking day______________________ 
* Average units (30ml sprit; 60ml wine; 1/2 mug beer = 1 unit) 
26. Family history in first-degree relatives: 
1. Tobacco use: a) Yes b) No 
27. Physical examination: 
Weight: ________ 
Height: ________ 
28. Motivational stage assessment:  
(a) Pre contemplation (b) contemplation (c) Preparation (d) action (e) Maintenance 
29. Diagnosis of tobacco habit: 1. Smoking 2. Smokeless 3. Both  
Follow up 
visit 
Follow 
up 
Date Tobacco 
use and 
quit 
status 
1% 
toluidine 
blue 
staining 
Measurement 
of the size of 
the lesion in 
mm 
Histological grading 
at baseline and 3rd 
month  
Baseline       
15th day        
45th day       
Third month       
 
Follow up: 1. No change 2. Reduced use 3. Stopped use 4. Lost to follow up 5. Relapse 
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PHOTOCOPIES OF AUTHENTICATION CERTIFICATES OF RAW DRUGS 
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